Akcea Therapeutics Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2014)
Status: Acquired by Ionis Pharmaceuticals, Inc. (2020)

Organization Overview

First Clinical Trial
2014
NCT02211209
First Marketed Drug
2018
inotersen (tegsedi)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Akcea Therapeutics | AKCEA THERAPS